12 Health Care Stocks Moving In Thursday's After-Market Session

BenzingaSep 26 16:31 ET

Buy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus Treatment

TipRanksSep 25 13:15 ET · Ratings

PRISM MarketView Features Q&A With Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

GlobeNewswireSep 25 08:30 ET

Lipella Pharmaceuticals Announces Update On Phase 2a Trial Of LP-310 In Oral Lichen Planus; Three Participants Completed The Four-week Treatment, Says Treatment Was Well Tolerated And Had No Unpleasant Taste

BenzingaSep 24 08:16 ET

Express News | Lipella Pharmaceuticals Inc - Trial to Conclude by Mid-2025, Top-Line Data by Year-End 2024

ReutersSep 24 08:00 ET

Express News | Lipella Pharmaceuticals Inc - LP-310 Treatment Well Tolerated With No Unpleasant Taste

ReutersSep 24 08:00 ET